$SLGL News
Last published 4w ago
- 4w agoSLGLKOL Investor Event - SOL-GEL TECHNOLOGIES LTDEarnings Call TranscriptsGood afternoon to our guests that took the trouble to visit us here and to everyone that is listening to us and the soldier team that are also watching us in Israel and is our biggest support when we are along this journ
- 4w agoSLGLKOL Investor Event - SOL-GEL TECHNOLOGIES LTDEarnings Call TranscriptsGood afternoon to our guests that took the trouble to visit us here and to everyone that is listening to us and the soldier team that are also watching us in Israel and is our biggest support when we are along this journ
- 1mo agoSLGLSol-Gel Technologies Announces Last Patient Last Visit in Pivotal Phase 3 Clinical Trial of SGT-610 in Gorlin SyndromeGlobeNewswireLast patient has completed the last scheduled study visit in the pivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndromeTop-line results remain on track for late November 2026 NESS ZIONA,
- 2mo agoSLGLSol-Gel Reports Second Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswirePivotal Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome remains ongoing, with top-line results on track for anticipated readout in late November 2026Sol-Gel has initiated a proof-of-concept
- 5mo agoSLGLSol-Gel Reports First Quarter 2026 Financial Results and Provides Corporate UpdatesGlobeNewswireSol-Gel received a Notice of Allowance for a method-of-use patent extending intellectual property protection for topical patidegib (SGT-610) until 2044Sol-Gel completed an oversubscribed underwritten offering, raising
- 7mo agoSLGLSol-Gel Technologies Ltd. Announces Pricing of Oversubscribed Underwritten OfferingGlobeNewswireNESS ZIONA, Israel, March 23, 2026 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL) today announced the pricing of an underwritten offering of 459,112 ordinary shares (the "Shares") at a
- 10mo agoSLGLSol-Gel Provides Update Following Unblinding of Phase 1b Study of SGT-210 in Darier DiseaseGlobeNewswireNESS ZIONA, Israel, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with rare and severe skin conditions, today provided an update
- 11mo agoSLGLVTRSSol-Gel Reports Third Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswireSol-Gel intends to pursue high-frequency BCC as an additional indication for its lead drug candidate SGT-610, which, if approved, could at least double the drug's commercial potentialIn September 2025, Sol-Gel announced
- 1y agoSLGLSol-Gel Announces Health Canada Approval of EPSOLAY®GlobeNewswireNESS ZIONA, Israel, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase-3 clinical
- 1y agoSLGLSol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate UpdatesGlobeNewswirePatient enrollment for our ongoing Phase-3 clinical trial of SGT-610 for Gorlin Syndrome has been completed; top-line results are expected in the fourth quarter of 2026Phase-1b proof-of-concept clinical trial of SGT-210
- 1y agoSLGLSol-Gel Reports First Quarter 2025 ResultsGlobeNewswireNESS ZIONA, Israel, May 23, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company, today announced financial results for the first quarter ended March 31, 2025.
- 1y agoSLGLSol-Gel Announces Reverse Share SplitGlobeNewswireNESS ZIONA, Israel, May 01, 2025 (GLOBE NEWSWIRE) -- Sol-Gel Technologies Ltd. (the "Company") (NASDAQ:SLGL), a clinical-stage dermatology company, today announced a reverse share split (the "Reverse Split") of the
- 1y agoSLGLSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.GlobeNewswireSol-Gel to receive $16 million during 2025Cash runway is expected to extend into the first quarter of 2027; Company expects to have sufficient cash to complete its Phase III clinical trialSGT-610 Phase III clinical trial
- 1y agoSLGLSol-Gel Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid RequirementGlobeNewswireNESS ZIONA, Israel, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial
- 1y agoSLGLSol-Gel Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswireMori Arkin's appointment as interim CEO as of January 1, 2025 approved by shareholdersPhase 3 clinical trial of SGT-610 for Gorlin Syndrome is ongoing with over 40 clinical sites activatedSGT-210 proof-of-concept
- 2y agoSLGLSol-Gel Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswireFollowing recent transactions and cost-cutting efforts, Sol-Gel's cash runway is expected to extend into the first quarter of 2026Ongoing Phase 3 clinical trial of SGT-610 for Gorlin Syndrome with over 30 clinical sites
- 2y agoSLGLSol-Gel Announces the Signing of Six Exclusive License Agreements to Commercialize TWYNEO® and EPSOLAY® in Europe and South AfricaGlobeNewswireNESS ZIONA, Israel, July 25, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial
- 2y agoSLGLSol-Gel Technologies Announces Management RealignmentGlobeNewswireNESS ZIONA, Israel, July 15, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial
- 2y agoSLGLSol-Gel Announces Receipt of Nasdaq Minimum Price NoticeGlobeNewswireNESS ZIONA, Israel, May 28, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial
- 2y agoSLGLSol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewswirePhase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened, is ongoing. Sol-Gel and Beimei Pharma announced an Asset Purchase Agreement to commercialize TWYNEO® in China, Hong Kong, Macau,
- 2y agoSLGLSol-Gel and Beimei Pharma Announce an Asset Purchase Agreement to Commercialize TWYNEO® in the Mainland of China, Hong Kong, Macau, Taiwan and IsraelGlobeNewswireNESS ZIONA, Israel, May 16, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial
- 2y agoSLGLSOL-GEL TECHNOLOGIES LTD. - Appeal, ReversedUS Patent Trial and Appeal Board
- 2y agoARQTSLGLSol-Gel's Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® CreamGlobeNewswireNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial
- 2y agoSLGLSol-Gel Reports Full-Year 2023 Financial Results and Corporate DevelopmentsGlobeNewswireAn ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel,
- 2y agoSLGLSol-Gel Technologies Screens First Patient for SGT-610 Phase 3 StudyGlobeNewswireSGT-610 has "Orphan Drug" designation status in the U.S. and E.U. and "Breakthrough Therapy" designation status in the U.S., as potentially the first and only therapy aimed at preventing new BCCs in Gorlin
- 2y agoSLGLSol-Gel Technologies Ltd to Host Virtual KOL Event on Gorlin Syndrome and the Upcoming Phase 3 Trial for SGT-610GlobeNewswireEvent to be held on December 6, 2023 will focus on preventing basal cell carcinomas associated with Gorlin syndrome with a discussion of the disease burden, SGT-610 and the upcoming Phase 3 trial NESS ZIONA, Israel,
- 3y agoSLGLSol-Gel Technologies Reports Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireSol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023Gorlin Syndrome KOL event to be held on December 6, 2023Sol-Gel maintains cash runway into the
- 3y agoSLGLSol-Gel Technologies to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireNESS ZIONA, Israel, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company leveraging innovative approaches to develop pioneering treatments for patients with severe skin
- 3y agoSLGLSol-Gel Technologies Reports Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswireSol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for Gorlin syndrome into Phase 3 testing in late 2023 Sol-Gel's recently announced agreement with Searchlight Pharma will provide up to $11
- 3y agoSLGLSol-Gel and Searchlight Pharma Announce Licensing Agreements to Commercialize TWYNEO® and EPSOLAY® in CanadaGlobeNewswireSol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to high-teensNon-dilutive capital
- 3y agoSLGLSol-Gel Technologies Reports First Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswirePositive trends continue for TWYNEO® and EPSOLAY® with recurrent prescriber bases at 98% for TWYNEO and 92% for EPSOLAY during Q1 2023 Sol-Gel on track to advance Orphan Drug candidate, SGT-610 (patidegib) for
- 3y agoSLGLSol-Gel Technologies to Present at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual ConferenceGlobeNewswireNESS ZIONA, Israel, March 20, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company with two innovative dermatology products that were launched in the U.S. and an innovative pipeline,
- 3y agoSLGLSol-Gel Reports Full-Year 2022 Financial Results and Corporate DevelopmentsGlobeNewswireRecent acquisition of Phase 3-ready SGT-610 (patidegib), an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndromeA Phase
- 3y agoSLGLSol-Gel Announces Aggregate $22.8 Million Concurrent Registered Direct and Private Placement OfferingsGlobeNewswireNESS ZIONA, Israel, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL) ("Sol-Gel" or the "Company"), a dermatology company with FDA approvals for EPSOLAY® and TWYNEO®, two innovative
- 3y agoSLGLSol-Gel Acquires Patidegib, a Phase 3, FDA-Breakthrough-Designated Orphan Product Candidate to Pursue Potential Market of Over $300 MillionGlobeNewswirePatidegib, an Orphan Drug candidate, broadens Sol-Gel's pipeline with the potential to be the first therapy for preventing new basal cell carcinomas in Gorlin syndrome, if approved by the FDAPhase 3 study expected to
- 4y agoSLGLSol-Gel Technologies Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireGrowth trends for TWYNEO and EPSOLAY continue to improve, demonstrating robust uptake by prescribersSol-Gel's cash runway expected to extend through the end of the first quarter of 2024 NESS ZIONA,
- 4y agoSLGLSOL-GEL TECHNOLOGIES LTD. - Appeal, AffirmedUS Patent Trial and Appeal Board
- 4y agoSLGLSol-Gel Technologies Appoints Michael Glezin Vice President, Business DevelopmentGlobeNewswireNESS ZIONA, Israel, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of ski
- 4y agoSLGLGalderma Launches EPSOLAY® Cream, a Medical Advance to Treat Bumps and Blemishes of RosaceaPR NewswireFDA-approved EPSOLAY (benzoyl peroxide) Cream, 5% is now available by prescription across the U.S. FORT WORTH, Texas, June 2, 2022 /PRNewswire/ -- Galderma announced today the availability of EPSOLAY (benzoyl peroxide) Cream, 5% in the U.S. following
- 4y agoSLGLSol-Gel Technologies to Participate in the 2022 Jefferies Global Healthcare ConferenceGlobeNewswireNESS ZIONA, Israel, June 01, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of ski
- 4y agoSLGLSol-Gel Technologies to Present in Upcoming H.C. Wainwright Global Investment ConferenceGlobeNewswireNESS ZIONA, Israel, May 17, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing, commercializing or partnering branded and generic topical drug products for the treatment of skin
- 4y agoSLGLSol-Gel Technologies Reports First Quarter 2022 Financial Results and Provides Corporate UpdateGlobeNewswireFDA approval for EPSOLAY® (benzoyl peroxide, cream, 5%) represents Sol-Gel's second approved product within less than a year; EPSOLAY is patent protected until 2040 Partner Galderma to launch two products in the U.S. this quarter: TWYNEO launched in t
- 4y agoSLGLSol-Gel Technologies and Galderma Announce FDA Approval of EPSOLAY®GlobeNewswireEPSOLAY (benzoyl peroxide, cream, 5%) utilizes Sol-Gel's proprietary microencapsulation technology for the treatment of inflammatory lesions of rosacea and is patent protected until 2040 Galderma set to commercialize EPSOLAY in the U.S. under exc
- 4y agoSLGLApproval of Epsolay, Nda #214510FDA Approved DrugsApproval Date: 04/22/2022; Drug Name: Epsolay, Nda #214510; Active Ingredients: BENZOYL PEROXIDE; Company: Sol-gel Technologies; Submission Status: Approval; Application Number: 214510
- 4y agoSLGLSol-Gel Technologies Announces the Commercial Availability of TWYNEO®GlobeNewswireTWYNEO is the first-ever tretinoin and benzoyl peroxide combination to treat facial acne Sol-Gel's U.S. commercialization partner, Galderma, launched TWYNEO® in the U.S. at the Annual Meeting of the American Academy of Dermatology, March 25-29, 2022 i
- 4y agoSLGLSol-Gel Technologies Reports Full Year 2021 Financial Results and Corporate DevelopmentsGlobeNewswireGalderma launched TWYNEO® at the Annual Meetings of the American Academy of Dermatology, March 25-29, 2022 in Boston, MA. TWYNEO will be commercially available in Spring 2022. 2021 revenue of $31.3 million Sol-Gel to receive $21.5 million over 24 mo
- 4y agoSLGLSol-Gel Technologies Announces U.S. Commercial Partner Galderma to Promote TWYNEO® at the American Academy of Dermatology Annual Meeting to be Held March 25-29 in Boston, MAGlobeNewswireNESS ZIONA, Israel, March 25, 2022 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases
- 4y agoSLGLGalderma Launches TWYNEO® Cream, the First Ever Tretinoin and Benzoyl Peroxide Combination to Treat Facial AcnePR NewswireFORT WORTH, Texas, March 25, 2022 /PRNewswire/ -- Galderma announced today the U.S. launch of TWYNEO (tretinoin and benzoyl peroxide) Cream, 0.1%/3% at the American Academy of Dermatology (AAD) Annual Meeting, March 25-29, 2022, in Boston, Massachusetts
- 4y agoSLGLSol-Gel Technologies to Participate in Upcoming LifeSci Partners Corporate Access Event and H.C. Wainwright BioConnect 2022 Healthcare ConferenceGlobeNewswireNESS ZIONA, Israel, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of s
- 4y agoSLGLSol-Gel Technologies Announces Positive Update Related to FDA Review Status of EPSOLAY®GlobeNewswireFDA informs Sol-Gel that it intends to conduct a pre-approval inspection of the production site for EPSOLAY during the week of February 14th, 2022 NESS ZIONA, Israel, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a